These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25724918)

  • 1. Measuring the cost effectiveness of HIV prevention interventions in the US: pitfalls and problems.
    Hellinger FJ
    Appl Health Econ Health Policy; 2015 Apr; 13(2):129-33. PubMed ID: 25724918
    [No Abstract]   [Full Text] [Related]  

  • 2. A systematic review on cost effectiveness of HIV prevention interventions in the United States.
    Huang YL; Lasry A; Hutchinson AB; Sansom SL
    Appl Health Econ Health Policy; 2015 Apr; 13(2):149-56. PubMed ID: 25536927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the Cost-Effectiveness of HIV Prevention Programmes in Vietnam, 2006-2010: A Modelling Study.
    Pham QD; Wilson DP; Kerr CC; Shattock AJ; Do HM; Duong AT; Nguyen LT; Zhang L
    PLoS One; 2015; 10(7):e0133171. PubMed ID: 26196290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness of female sex worker interventions by using SEX 2.0 Tool in Dehong prefecture, Yunnan province].
    Guo HY; Duan S; Xiang LF; Ye RH; Yang YC; Zhang H; Yuan JH; Cao WH; Xing Y; Sun JP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2010 Aug; 44(8):717-20. PubMed ID: 21055022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of a community-level HIV risk reduction intervention for women living in low-income housing developments.
    Johnson-Masotti AP; Pinkerton SD; Sikkema KJ; Kelly JA; Wagstaff DA
    J Prim Prev; 2005 Jul; 26(4):345-62. PubMed ID: 15995803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Threshold analysis and programs for prevention of HIV infection.
    Holtgrave DR; Qualls NL
    Med Decis Making; 1995; 15(4):311-7. PubMed ID: 8544675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of HIV prevention programs.
    Holtgrave DR; Qualls NL; Graham JD
    Annu Rev Public Health; 1996; 17():467-88. PubMed ID: 8724236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost savings threshold analysis of a capacity-building program for HIV prevention organizations.
    Dauner KN; Oglesby WH; Richter DL; LaRose CM; Holtgrave DR
    AIDS Educ Prev; 2008 Jun; 20(3):265-74. PubMed ID: 18558823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health reform: what's prevention got to do with it?
    Blacksher E
    Hastings Cent Rep; 2009; 39(6):inside back cover. PubMed ID: 20050370
    [No Abstract]   [Full Text] [Related]  

  • 10. Using Misoprostol for Primary versus Secondary Prevention of Postpartum Haemorrhage - Do Costs Matter?
    Chatterjee S; Sarkar A; Rao KD
    PLoS One; 2016; 11(10):e0164718. PubMed ID: 27755601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
    Younis T; Rayson D; Jovanovic S; Skedgel C
    Breast Cancer Res Treat; 2016 Oct; 159(3):425-32. PubMed ID: 27572552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention and private health insurance].
    Brüggenjürgen B
    Dtsch Med Wochenschr; 2011 Feb; 136(5):218-22. PubMed ID: 21271487
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
    Ramsey SD; Liu Z; Boer R; Sullivan SD; Malin J; Doan QV; Dubois RW; Lyman GH
    Value Health; 2009; 12(2):217-25. PubMed ID: 18673353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
    Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
    J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The president's fiscal year 2007 initiative for human immunodeficiency virus counseling and testing expansion in the United States: a scenario analysis of its coverage, impact, and cost-effectiveness.
    Holtgrave DR
    J Public Health Manag Pract; 2007; 13(3):239-43. PubMed ID: 17435490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Numerical optimal control for HIV prevention with dynamic budget allocation.
    Gromov D; Bulla I; Silvia Serea O; Romero-Severson EO
    Math Med Biol; 2018 Dec; 35(4):469-491. PubMed ID: 29106566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.
    Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
    Cardiovasc Ther; 2013 Feb; 31(1):45-52. PubMed ID: 21884025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The costs of HIV prevention strategies in developing countries.
    Söderlund N; Lavis J; Broomberg J; Mills A
    Bull World Health Organ; 1993; 71(5):595-604. PubMed ID: 8261563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of and Financial Returns to Voluntary Medical Male Circumcision for HIV Prevention in South Africa: An Incremental Cost-Effectiveness Analysis.
    Haacker M; Fraser-Hurt N; Gorgens M
    PLoS Med; 2016 May; 13(5):e1002012. PubMed ID: 27138961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV prevention programmes for female sex workers in Andhra Pradesh, India: outputs, cost and efficiency.
    Dandona L; Sisodia P; Kumar SG; Ramesh YK; Kumar AA; Rao MC; Marseille E; Someshwar M; Marshall N; Kahn JG
    BMC Public Health; 2005 Sep; 5():98. PubMed ID: 16181491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.